While we get ready to evolve to a new format for the rest of the summer, we feel like it’s a good day to check in on COVID-19 and how far we’ve come—thanks to the biotech industry’s efforts we’ve been covering for 4+ years. Plus, a proposed rule change from CMS represents a positive step toward better patient access to cutting-edge Alzheimer’s treatments. (624 words, 3 minutes, 7 seconds)

Good Day BIO is evolving. Over the summer, Bio.News will bring you a weekly digest every Monday at 10 A.M. ET, plus breaking news alerts as needed. This transition period will allow us to analyze feedback and analytics and develop even better communications to meet your needs. This week: BIO Board member Frank Watanabe's testimony at a House hearing, an exclusive interview with Sen. Richard Burr on the legacy of Project BioShield, the latest on bird flu and PBMs, and how you can follow the RNC, which kicks off today. As always, we're keeping it tight, at 811 words, 4 minutes, 3 seconds.P.S. It’s not too late to complete the 3-minute reader survey and weigh in on BIO’s media content and communications! 

We have details on BIO’s comments on a U.S. Patent and Trademark Office proposal that would harm the patent system—plus, more groundbreaking companies featured at the NIH Innovation Zone at BIO 2024 and how to nominate a leader for the California Life Sciences Pantheon Awards. Don’t forget to take our reader survey! (623 words, 3 minutes, 6 seconds)

At long last, the FTC released an interim report on PBMs—and the findings are not surprising. We have details, plus more about the winners of BIO’s 2024 Agri-Biotechnology Awards. Don’t forget to take our reader survey! (523 words, 2 minutes, 36 seconds)

Today, we have news on Boehringer Ingelheim’s new biomass power plant and the expanding range of lone star ticks—plus, how you can weigh in on what’s next for BIO’s communications products. (731 words, 3 minutes, 39 seconds)

Congress heads back to work, and we catch up on news including the FDA’s approval of Eli Lilly’s Alzheimer’s drug and what happened at the U.S.-Mexico-Canada Agreement dispute panel on Mexico’s biotech corn ban. (618 words, 3 minutes, 5 seconds)We want your feedback! We are conducting a survey to get reader feedback on the Good Day BIO newsletter and ensure our content best meets your needs. Click here to take our short survey.